Effect of monoamine oxidase inhibitors on formation of morphine glucuronide.
D000818:Animals; D002247:Carbon Isotopes; D005965:Glucuronates / Q000096:biosynthesis; D006602:Hexosyltransferases / Q000037:antagonists & inhibitors*; D066298:In Vitro Techniques; D007520:Isocarboxazid / Q000494:pharmacology; D007700:Kinetics; D008297:Male; D008862:Microsomes, Liver / Q000187:drug effects / Q000201:enzymology* / Q000378:metabolism; D008996:Monoamine Oxidase Inhibitors / Q000494:pharmacology*; D009020:Morphine / Q000378:metabolism*; D009526:Nialamide / Q000494:pharmacology; D009702:Nucleoside Diphosphate Sugars; D010293:Pargyline / Q000494:pharmacology; D010624:Phenelzine / Q000494:pharmacology; D051381:Rats; D014191:Tranylcypromine / Q000494:pharmacology; D014500:Uracil Nucleotides
D002247:Carbon Isotopes; D005965:Glucuronates; D008996:Monoamine Oxidase Inhibitors; D009702:Nucleoside Diphosphate Sugars; D014500:Uracil Nucleotides; D007520:Isocarboxazid; D014191:Tranylcypromine; D009020:Morphine; D010293:Pargyline; D006602:Hexosyltransferases; D010624:Phenelzine; D009526:Nialamide